Consensus Bolt Biotherapeutics, Inc.

Stocks

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2026-09-04 EDT			5-day change	1st Jan Change
3.900 ^USD	+0.13%		+2.23%	-28.68%

08-11	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE

Evolution of the Average Target: Bolt Biotherapeutics, Inc.

Evolution of the Target Price: Bolt Biotherapeutics, Inc.

Changes in Analyst Recommendations: Bolt Biotherapeutics, Inc.

9a02312f0cb0f64ac6e88b.dQ476UQZcnqvFiFYdqacaPM4k9nYcK2jpiDW9bFnZXw.EWVsp2l-P0ruT1QBMPLfGcRC0eG3Gvj34UK7sOUIKi0nawrEAkgVQ9xhFQ~47bf30d1682e50f58851c9062ad2a61d

Analysts' recommendations: Bolt Biotherapeutics, Inc.

24-05-15	Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	MT
24-05-15	Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
24-05-15	HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
24-05-15	Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
23-05-12	SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4	MT
23-01-24	Morgan Stanley Cuts Price Target on Bolt Biotherapeutics to $3 From $5, Maintains Equal-Weight Rating	MT
22-10-04	HC Wainwright Starts Bolt Biotherapeutics at Buy With $8 Price Target	MT
22-08-11	Stifel Nicolaus Lowers Price Target for Bolt Biotherapeutics to $7 From $13, Maintains Buy Rating	MT
22-08-11	SVB Securities Downgrades Bolt Biotherapeutics to Market Perform from Outperform, Adjusts Price Target to $4 from $8	MT
22-05-17	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating	MT
22-05-16	Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Rating	MT
22-02-01	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $7 from $11, Keeps Equalweight Rating	MT
22-01-06	Morgan Stanley Downgrades Bolt Biotherapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $45	MT
21-12-07	Stifel Adjusts Bolt Biotherapeutics' Price Target to $19 From $34, Reiterates Buy Rating	MT
21-11-10	SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $33 from $35, Keeps Outperform Rating	MT
21-08-16	Bolt Biotherapeutics : SVB Leerink Raises Bolt Biotherapeutics' Price Target to $35 From $34, Maintains Outperform Rating	MT
21-04-06	Bolt Biotherapeutics : SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $37 From $36, Maintains Outperform Rating	MT
21-03-02	Bolt Biotherapeutics : Morgan Stanley Starts Bolt Biotherapeutics at Overweight With $45 Price Target	MT
21-03-02	Bolt Biotherapeutics : SVB Leerink Starts Bolt Biotherapeutics at Outperform With $36 Price Target	MT
21-03-02	Bolt Biotherapeutics : Stifel Starts Bolt Biotherapeutics at Buy With $40 Price Target	MT
21-03-02	Bolt Biotherapeutics : Guggenheim Starts Bolt Biotherapeutics at Buy With $42 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BOLT BIOTHERAPEUTICS, INC.					+643.59%
	WUXI APPTEC CO., LTD.					+21.09%
	ARGENX SE					+11.95%
	INSMED INCORPORATED					+58.51%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.61%
	BIONTECH SE					+15.94%
	GENMAB A/S					+12.11%
	PHARMAESSENTIA CORPORATION					+6.66%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.36%
	EXELIXIS, INC.					-9.02%
	Average					+80.38%
	Weighted average by Cap.					+18.95%